Victoza

  • Victoza Medical Record Review & Outsourcing Services

Victoza (Liraglutide) is a long-acting glucagon-like peptide-1 receptor agonist. It was approved by U.S. Food and Drug Administration (FDA) on January 25, 2010. It is manufactured by Danish drug maker Novo Nordisk and was launched in the U.S. in February 2010 and in the EU in July 2009.

It acts by binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. It mimics the GLP-1 (glucagon-like peptide-1) hormone and controls the blood glucose level when given along with diet and exercise, in adult patients with Type 2 diabetes mellitus. The injectable form works by stimulating insulin production.

Serious Alleged Injuries may include:

  • Hypoglycemia
  • Kidney failure
  • Severe allergic reaction
  • Pancreatitis
  • Pancreatic cancer
  • Thyroid cancer

FDA SAFETY WARNINGS:

  • On June 14, 2011, the warning had been issued by the FDA for Victoza about the risks of thyroid cancer and pancreatitis. The agency also highlighted the contraindication for liraglutide in patients with a personal or family history of medullary thyroid cancer or a personal history of multiple endocrine neoplasia syndrome type 2.
  • On April 9, 2012, the FDA gave approval for updating the label regarding the superior blood glucose control when compared to Januvia.
  • In April 2013, warnings and precautions included acute pancreatitis, fatal and non-fatal hemorrhagic and necrotizing pancreatitis.
  • In March 2015, black box warning, warnings, and precautions were modified adding the risk of thyroid C- cell tumors including medullary thyroid carcinoma (MTC).

Lawsuit Allegations:

In 2013, Victoza lawsuits along with several diabetes medications (Byetta, Januvia, and Janumet) were centralized in a multidistrict litigation MDL 2452 (In Re: Incretin Mimetics Products Liability Litigation) in the Southern District of California. Lawsuits filed alleged that though the manufacturers knew about the link of their product to cancer side effects in several studies, the details were not made public. Victoza thyroid lawsuits were filed across the nation, claiming that the drug caused patients to develop thyroid and pancreatic cancer.

In November 2015, the Judge Battaglia, granted a summary judgment in favor of the defendants, following a preemption protocol dismissing all the cases in the MDL.

In September 2016, plaintiff attorneys filed an appeal to the Ninth Circuit U.S. Court of Appeals on behalf of the MDL stating that Judge Battaglia misinterpreted the U.S. Supreme Court preemption law.

Evidences:

  • Usage of Victoza in Pharmacy Records
  • Duration of Victoza usage
  • Indications for usage of Victoza in Medical Records
  • Complications and their treatment after Victoza Intake

Medical Record Review and claim validation of Victoza case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.

Accreditations

HIPAA

Neural IT has successfully implemented HIPAA for securing Health records....

ISO 27001 Certification

Neural IT has successfully passed the ISMS re-certification audit and is now ISO 27001:2013 certi...

NSIC - CRISIL

NSIC-CRISIL has assigned a "SE 2A" rating to Neural IT, indicating a company with High Performanc...

Associations

CAALA

CAALA - "Neural IT is proud to be associated with CAALA (Consumer Attorneys Association of Los An...

CAOC

CAOC - "Neural IT is proud to be associated with CAOC (Consumer Attorneys of California) as a Ven...

NYSTLA

NYSTLA - "Neural IT is proud to be associated with NYSTLA (New York State Trial Lawyers Associati...

News & Events

Thanksgiving 2018 Celebration at Neural IT
Thanksgiving 2018 was celebrated at Neural IT with a bash to express appreciation for each other
October 20, 2018, Picnic to the Water Kingdom
October 20, 2018, Picnic to the Water Kingdom turned out to be the most exciting and fun-filled d
A Click with Peyton Manning at MTMP Fall Conference 2018
A Click with Peyton Manning at MTMP Fall Conference 2018.

Latest Tweets